

PCR-/NAT *Helicobacter pylori*
(RV 533) Juni 2017



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
1715331	+++	61/71	<i>Helicobacter pylori</i> (~ 5x10 ⁵ CFU/mL) Clarithromycin resistant (GGA mut. in 23S rDNA)
1715332	++	61/71	<i>Helicobacter pylori</i> (~ 5x10 ⁴ CFU/mL) Clarithromycin resistant (GGA mut. in 23S rDNA)
1715333	∅	62	<i>Escherichia coli</i> K12
1715334	+	61/71	<i>Helicobacter pylori</i> (~ 5x10 ³ CFU/mL) Clarithromycin resistant (GGA mut. in 23S rDNA)

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

<i>n = 50</i>	<i>Probennummer (Sample no.)</i>				<i>Inhibition</i>				
	1715331	1715332	1715333	1715334	1715331	1715332	1715333	1715334	
Befund <i>Result</i>									
Positiv	50 ¹⁾	50 ¹⁾	1	49 ¹⁾	n.d.	1	1	1	1
Negativ	0	0	49	1	nein <i>no</i>	49	49	49	49
Fraglich <i>Questionable</i>	0	0	0	0	ja <i>yes</i>	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv <i>True positive results</i>			NAT richtig negativ <i>True negative results</i>		
	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%
Hain GenoType Helico [20] (n = 21)	63	63 / 63	100	21	21 / 21	100
Ingenetix ClariRes [21] (n = 1)	3	3 / 3	100	0	0 / 1	0
r-Biopharm RIDAGENE [22] (n = 5)	15	15 / 15	100	5	5 / 5	100
Commercial assay [27] (n = 4)	11	11 / 12	92	4	4 / 4	100
<i>In house</i> PCR assay [28] (n = 20)	60	60 / 60	100	20	20 / 20	100

* Durch Mehrfachnennung oder fehlende Angabe kann die absolute Zahl der Ergebnisse (Tab. 2) von der Anzahl der Teilnehmer abweichen.
Due to reporting results of multiple assay systems or missing specifications, the effective numbers are not correlating with the number of participants

Comments: ¹⁾ Thirty-nine of the 50 participants reported results for molecular Clarithromycin-susceptibility testing. All reported results were correct.